Aug 8 |
Intellia hereditary angioedema candidate meets phase 2 primary endpoint
|
Aug 8 |
Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study
|
Aug 8 |
Intellia Therapeutics, Inc. (NTLA) Q2 2024 Earnings Call Transcript
|
Aug 8 |
Intellia Therapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
Aug 8 |
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
|
Aug 8 |
Intellia Therapeutics GAAP EPS of -$1.52 misses by $0.29, revenue of $6.96M misses by $11.29M
|
Aug 8 |
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
|
Aug 7 |
Intellia Therapeutics Q2 2024 Earnings Preview
|
Aug 6 |
The 3 Best Cathie Wood Stocks to Buy in August 2024
|
Aug 3 |
Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
|